大葉大學圖書館 |

Intracellular delivery III[electronic resource] :market entry barriers of nanomedicines /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.6
書名/作者:	Intracellular delivery III : market entry barriers of nanomedicines // edited by Ales Prokop, Volkmar Weissig.
其他作者:	Prokop, Ales.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	xiii, 453 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Drug delivery systems.
標題:	Nanomedicine.
標題:	Biomedicine.
標題:	Biomedicine general.
標題:	Nanotechnology.
ISBN:	9783319435251
ISBN:	9783319435237
摘要、提要註:	A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new "drugs" will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently "nanomaterials" have been said to "show promise" but none of these promises have so far been "reduced" to human clinical practice. The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies) Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug-carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile.
電子資源:	http://dx.doi.org/10.1007/978-3-319-43525-1

Intracellular delivery III[electronic resource] :market entry barriers of nanomedicines /
Intracellular delivery IIImarket entry barriers of nanomedicines /[electronic resource] :edited by Ales Prokop, Volkmar Weissig. - Cham :Springer International Publishing :2016. - xiii, 453 p. :ill., digital ;24 cm. - Fundamental biomedical technologies,v.81559-7083 ;. - Fundamental biomedical technologies ;v.7..

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new "drugs" will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently "nanomaterials" have been said to "show promise" but none of these promises have so far been "reduced" to human clinical practice. The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies) Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug-carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile.

ISBN: 9783319435251

Standard No.: 10.1007/978-3-319-43525-1doiSubjects--Topical Terms:

386389
Drug delivery systems.

LC Class. No.: RS199.5

Dewey Class. No.: 615.6

Intracellular delivery III[electronic resource] :market entry barriers of nanomedicines /
LDR:02899nam a2200313 a 4500 001 476373
003 DE-He213
005 20161101043631.0
006 m d
007 cr nn 008maaau
008 181208s2016 gw s 0 eng d
020 $a 9783319435251 $q (electronic bk.)
020 $a 9783319435237 $q (paper)
024 7 $a 10.1007/978-3-319-43525-1 $2 doi
035 $a 978-3-319-43525-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RS199.5
072 7 $a MBGR $2 bicssc
072 7 $a MED000000 $2 bisacsh
082 0 4 $a 615.6 $2 23
090 $a RS199.5 $b .I61 2016
245 0 0 $a Intracellular delivery III $h [electronic resource] : $b market entry barriers of nanomedicines / $c edited by Ales Prokop, Volkmar Weissig.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a xiii, 453 p. : $b ill., digital ; $c 24 cm.
490 1 $a Fundamental biomedical technologies, $x 1559-7083 ; $v v.8
520 $a A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new "drugs" will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently "nanomaterials" have been said to "show promise" but none of these promises have so far been "reduced" to human clinical practice. The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies) Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug-carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile.
650 0 $a Drug delivery systems. $3 386389
650 0 $a Nanomedicine. $3 342485
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Biomedicine general. $3 463541
650 2 4 $a Nanotechnology. $3 192698
700 1 $a Prokop, Ales. $3 467705
700 1 $a Weissig, Volkmar. $3 687079
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Fundamental biomedical technologies ; $v v.7. $3 588597
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-43525-1
950 $a Biomedical and Life Sciences (Springer-11642)